Every trade and directional call the AI fund has made on UNH, newest first, each linked to that day's full decision.
Negative five-day and 30-day returns indicate unfavorable relative momentum despite constructive analyst commentary.
Negative returns from cost and across both 5-day and 30-day periods show the clearest held-position deterioration.
The 5.9% 30-day decline and position below cost indicate continuing relative weakness despite a positive five-day move.
The stock is below cost and down 4.1% over 30 days, despite a small five-day rebound.
Negative 5-day and 30-day momentum, combined with a loss versus cost, indicate persistent relative weakness.
UNH is below cost and negative over five and 30 days, indicating unresolved relative weakness despite valuation-support commentary.
The position is materially below cost and supplied news emphasizes its discount after a substantial decline, requiring evidence of stabilization.
Negative 30-day momentum and a loss versus portfolio cost indicate continuing relative weakness despite modest recent stabilization.
UNH is below cost and negative over both five and 30 days, signaling sustained relative weakness.
The 6.03% 30-day decline and negative five-day performance indicate persistent weakness versus SPY.
The position is below cost with negative 5-day and 30-day momentum, leaving insufficient evidence of a confirmed recovery versus SPY.
The position is below cost and negative over both five and 30 days, with no supplied catalyst demonstrating stabilization.
Negative five-day and 30-day momentum while below portfolio cost indicates continued relative weakness.
UNH's 5.4% five-day and 7.3% 30-day declines are materially weaker than SPY and indicate persistent company-specific selling pressure.
Negative returns over both periods and a loss versus average cost indicate unresolved relative weakness.
Negative five-day and 30-day momentum, with no confirmed positive catalyst, favor continued lagging performance.
Negative 30-day performance, a position below cost, and current company-specific selling pressure argue for caution.
Negative 30-day momentum and a price slightly below cost provide insufficient evidence of recovery.
The negative 30-day return and price below cost outweigh the recent 5-day rebound.
Recent five-day recovery is not enough to overcome the negative 30-day return and below-cost position.
Negative 30-day performance, below-cost status and governance/margin uncertainty outweigh the recent small rebound.
Negative 5-day and 30-day returns, trading below cost, and unresolved margin-recovery concerns indicate relative weakness.
UNH is below cost and down 9.2% over 30 days, with additional negative five-day momentum and margin/governance uncertainty.
An -8.1% 30-day decline and price below portfolio cost outweigh the recent positive five-day bounce.
The stock is below cost and down 8.6% over 30 days, with insufficient evidence that the small five-day gain has repaired the trend.
UNH is down 7.5% over 30 days and remains below cost, indicating unfavorable relative momentum despite favorable earnings commentary.
UNH is below cost and shows negative momentum over both periods, despite supportive analyst commentary.
Below-cost status, an -8.21% 30-day return and governance-related uncertainty indicate unfavorable relative momentum.
Below-cost status, negative momentum and governance-related concerns support a cautious relative outlook.
A -7.0% 30-day return and price below cost show persistent weakness despite incremental member-access news.
Negative 5-day and 30-day momentum, combined with a price below portfolio cost, make this the clearest current holding weakness.
The 6.0% 30-day decline, negative five-day return, and price below portfolio cost indicate continued relative weakness.
The 6.0% 30-day decline and price below cost warrant caution despite a small five-day gain.
UNH is near cost and down 5.50% over 30 days, with medical-cost concerns adding to relative weakness.
UNH is below cost and down 4.54% over 30 days despite a marginally positive 5-day return and favorable guidance-related news.
Negative five-day and 30-day performance trails SPY despite favorable guidance-related headlines.
Near-zero to negative momentum with mixed recent results suggests cautious view.
UNH’s negative momentum and healthcare regulation risk point toward underperformance.
Near-zero momentum suggests limited upside but stable hold relative to SPY.
UnitedHealth stable fundamentals and slight negative momentum suggest performance close to SPY.
Slight positive momentum but sector uncertainties warrant neutral stance.
Strong Q2 earnings and good fundamentals favor slight outperformance.
Moderate positive momentum and defensive healthcare positioning support modest outperformance.
Positive earnings and sector strength support mild outperformance.
Strong healthcare fundamentals and positive news flow support above-market returns.
Modest positive 30-day return but recent faltering momentum suggest neutral performance.
Strong fundamentals and positive earnings support outperformance vs SPY.
UnitedHealth’s strong momentum and healthcare demand underpin outperformance vs SPY.
Modest momentum with steady fundamentals suggest performance close to SPY.
Positive earnings momentum and news support outperformance.
Stable earnings and market position point to modest outperformance.
Positive earnings guidance and moderate momentum support holding for market-like returns.
Stable momentum and defensive sector support outperformance amidst volatility.
Positive earnings outlook and stable momentum support UNH outperforming SPY.
Positive momentum and earnings outlook forecast outperformance.
Steady upward momentum and defensive healthcare positioning support outperformance.
Defensive sector strength and modest momentum give upside vs SPY.
Positive momentum and AI investment initiatives support growth relative to SPY.